Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Clinical Research Center for Digestive Diseases, Guangzhou, Guangdong, China
Auto-generated profile, based on publicly available information
Zhengran Zhou
Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Clinical Research Center for Digestive Diseases, Guangzhou, Guangdong, China
The heterogeneity of tumor immune microenvironment accounts for differential prognosis and immunotherapy responsiveness among colorectal cancer (CRC) patients. Here, we developed a novel immune classification for colorectal cancer through integrative multi-omics analysis. Immune-related gene expression, mutation, and methylation profiles were collected from two large-scale multi-omics CRC cohort (TCGA, n = 627; COCC, n = 977) to perform multi-omics factor analysis (MOFA) and establish the Multi-Omics Tumor Immune Features-based Clusters of CRC (MotifCC). The molecular differences and tumor immune variations among different clusters were analyzed and experimentally validated. Potential molecular targets for converting immune-cold tumors into hot tumors were validated with cell lines, patient-derived organoids (PDOs), and animal models. Integrative multi-omics analysis revealed three novel clusters with distinct characteristics. Cluster1, with high WNT pathway activation, had the worst prognosis and a tumor-promoting microenvironment. This immune-cold subtype may benefit from a combination of immunotherapy and WNT-targeted treatment. Cluster2 was characterized by low immune infiltration and high glycolysis intensity. These patients may benefit from treatment with metabolism inhibitors. Cluster3 was distinguished by high gene methylation, high tumor mutation burden, microsatellite instability, and better response towards immunotherapy. We successfully established the MotifCC, a novel multi-omics immune classification system for CRC. This system effectively captures the multi-omics heterogeneity of CRC, providing valuable insights for tailoring immunotherapy strategies and potentially improving patient outcomes.
Colorectal cancer (CRC) is among the leading causes of cancer-related deaths worldwide, predominantly caused by recurrence, underscoring the need for novel biomarkers for the early detection of relapse. We hypothesize that patients' response to cancer is closely linked to metabolic changes and can be detected in blood as an indicator for recurrence. Full metabolomics analysis was performed on the longitudinal samples collected from 160 patients with CRC before and after surgery for 24 months or more. Key blood metabolic biomarkers that distinguish relapse and non-relapse patients were identified, and a minimal residual disease (MRD) detection machine-learning model was constructed based on the discovered signatures. The model diagnosed CRC relapse with a sensitivity of 62% and specificity of 80%, with median and maximum lead times of 471 and 1056 days before diagnosed clinical relapse, suggesting it could be used as a novel diagnostic tool for the earlier detection of cancer relapse.